Battle between Gilead and U.S. government goes to trial; what to know about Lilly's Alzheimer's therapy readout

Taking stock of the drug industry, from the lab to the medicine chest

May 2, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Yichuan Cao/Sipa USA via AP Images STAT+ | A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial "The case is really about the use of patent infringement as a tool to effectuate changes in drug access and pricing policy," said IP expert Jacob Sherkow. By Ed Silverman STAT+ | Most of Canada's public research universities get bad grades for ensuring access to drugs they discover Many public research universities in Canada fail to enact policies that would ensure medicines they help discover are accessible worldwide. By Ed Silverman STAT+ | Disagreements and digs upend an otherwise bipartisan hearing on PBM reform The first Senate health committee markup under Chairman Bernie Sanders (I-Vt.) was rocky from the start — and downhill from there. By John Wilkerson Darron Cummings/AP STAT+ | What to know about the upcoming readout of Eli Lilly's experimental Alzheimer's therapy The approval of a similar medicine has wrung risk from the outcome, but for the same reason, expectations for strong results are higher. By Adam Feuerstein and Damian Garde STAT+ | Legal battle between Apple and Masimo over trade secrets ends in mistrial Masimo initially filed the suit against Apple in 2020, claiming that the tech giant stole trade secrets that it folded into its Apple Watch. By Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser